FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
latest-news-card-1
Human Drugs

Liebel-Flarsheim CGMP Violations Cited

FDA warns Liebel-Flarsheim in Raleigh, NC, about CGMP violations in its production of finished drugs.

latest-news-card-1
Human Drugs

Alembic Pharmaceuticals FDA-483 Out

FDA releases the form FDA-483 with four observations from an inspection at the Alembic Pharmaceuticals active pharmaceutical ingredient manufacturing ...

latest-news-card-1

HR Complaints Filed Against Prasad: Report

A STAT report highlighted in Medpage says CBER employees are concerned about the environment established by their new director, Vinay Prasad.

latest-news-card-1
Human Drugs

FDA Rejects Biohavens Troriluzole Application

FDA issues Biohaven a complete response letter, rejecting the companys NDA for Vyglxia (troriluzole) as a treatment for spinocerebellar ataxia.

latest-news-card-1
Human Drugs

FDA Warns Apotex Canadian Manufacturing Site

FDA issues a Warning Letter to Apotex, citing significant GMP violations at the companys Richmond Hill, Ontario, facility, including failures in steri...

Human Drugs

2 CGMP Issues in Scientific Protein Inspection

FDA warns Waunakee, WI-based Scientific Protein Laboratories about CGMP deviations in its manufacturing of active pharmaceutical ingredients.

FDA General

White House Supporting Makary in Turmoil: Report

Politico reports that President Trump and HHS are standing by FDA commissioner Marty Makary as the agency weathers the sudden departure of CDER direct...

latest-news-card-1
Human Drugs

FDA OKs Meitheals Antibiotic for Urinary Tract Infections

FDA approves a Meitheal Pharmaceuticals NDA for Contepo (fosfomycin) for injection for treating adults with complicated urinary tract infections.

Animal Drugs

Sydnexis Pediatric Myopia Drug Meets Endpoints

Sydnexis says its SYD-101 drug to treat pediatric progressive myopia met both the primary and key secondary endpoints in the Phase 3 STAR trial.

latest-news-card-1

Can Industry Accept a Dysfunctional FDA?: Axios

An Axios report following the resignation of CDER director George Tidmarsh questions how much more agency dysfunction industry can accept before simpl...